Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Arrowhead, Sanofi, Monsanto, and More


Title: Endosomolytic Polymers

Patent Number: 8,211,468

Filed: Sept. 9, 2006

Lead Inventor: David Rozema, Arrowhead Research

The invention, the patent's abstract states, relates to “delivery particles containing pH-sensitive endosomolytic polymers. The described particles are capable of delivering polynucleotides to cells from the peripheral circulation with subsequent release from endosomes. The endosomolytic polymers are inactive outside the cell but disrupt membranes upon exposure to an acidified endosomal compartment.”

Title: Methods and Compositions for Treating HIV Infection

Patent Number: 8,211,866

Filed: Jan. 14, 2006

Lead Inventor: Steven Zeichner, Children's Research Institute

The invention comprises “a method for treating latent HIV infection,” according to the patent's abstract. “The method includes administering to a subject in need of such treatment an effective amount of an anti-IkappaB-alpha agent ... and administering to the subject an effective amount of an antiviral agent. A pharmaceutical composition for treating latent HIV infection is also disclosed.”

The patent specifically claims the use of an siRNA targeting IkappaB-alpha.

Title: Methods and Compositions for Detection of Small RNAs

Application Number: 20120164651

Filed: April 13, 2010

Lead Inventor: Sergei Kazakov, Somagenics

The invention, the patent application's abstract states, “capitalizes on circularization of small RNA targets or their conjugates with oligonucleotide adapters. The circular RNA templates provide amplification of the target sequences via synthesis of multimer nucleic acids that can be either labeled for direct detection or subjected to PCR amplification and detection.

“Structure of small circular RNAs and corresponding multimeric nucleic acids provide certain advantages over current methods including flexibility in design of conventional RT and PCR primers as well as use of 5'-overlapping dimer-primers for efficient and sequence-specific amplification of short target sequences,” the abstract adds. The invention also “reduces the number of steps and reagents while increasing sensitivity and accuracy of detection of small RNAs with both 2'OH and 2'-OMe at their 3' ends … [and increases] sensitivity and specificity of detection of microRNAs and other small RNAs with both 2'OH and 2'-OMe at their 3' ends while allowing us to distinguish these two forms from each other.”

Title: Compositions for Silencing the Expression of VDAC1 and Uses Thereof

Application Number: 20120164730

Filed: Dec. 27, 2011

Lead Inventor: Varda Shoshan-Barmatz, Ben-Gurion University

The invention, the patent application's abstract states, “relates generally to the down-regulation of mitochondrial protein, voltage-dependent anion channel expression by RNAi or antisense therapy. In particular, the ... invention is directed to VDAC1 silencing molecules useful in regulating cell proliferation and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant cell proliferation.”

Title: Compositions and Methods for Therapy and Diagnosis of Cancer

Application Number: 20120165390

Filed: Nov. 21, 2011

Lead Inventor: Ugur Sahin, Ganymed Pharmaceuticals

The invention relates to “siRNA molecules [that] specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts,” the patent application's abstract states. “The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies. The ... invention also includes methods which make [it] possible to assess and/or prognose the metastatic behavior of a cancer disease and/or the occurrence of a relapse of cancer.”

Title: Use of Inhibitors of ZHDDC2 Activity for Modulation of Adipogenesis

Application Number: 20120165391

Filed: May 19, 2010

Lead Inventor: Diana Hall, Sanofi

The invention, the patent application's abstract states, concerns ZDHHC2, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in ZDHHC2 activity in adipose tissue induces a decrease in adipogenesis. Thus, the ... invention relates to modulators of ZDHHC2 activity, as well as [a] screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.”

Title: Peptide-Based In Vivo siRNA Delivery System

Application Number: 20120165393

Filed: Dec. 15, 2011

Lead Inventor: David Rozema, Arrowhead Research

The invention is “directed compositions for targeted delivery of RNA interference polynucleotides to hepatocytes in vivo,” the patent application's abstract states. “Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.”

Title: Chemical Modification of Short Small Hairpin RNAs for Inhibition of Gene Expression

Application Number: 20120165397

Filed: July 13, 2010

Lead Inventor: Qing Ge, Somagenics

“Aspects of the ... invention include the production and use of chemically modified RNAi agents in gene-silencing applications,” the patent application's abstract states. “The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the ... invention and kits containing the same are also provided.”

Title: snoRNAi-Small Nucleolar RNA Degradation by RNA Interference in Trypanosomatids

Application Number: 20120165399

Filed: March 12, 2012

Inventor: Shulamit Michaeli, Bar-Ilan University

The invention, the patent application's abstract states, comprises “polynucleotides and a method suitable for downregulation of small nuclear RNA which can be used to treat diseases associated with activity of small nuclear RNA. ... Specifically, the ... invention can be used to downregulate snoRNA molecules or box H/ACA-containing RNA molecules which are involved in diseases such as cancer.”

Title: Temporal Regulation of Gene Expression by microRNAs

Application Number: 20120167258

Filed: June 26, 2008

Lead Inventor: Edwards Allen, Monsanto

“This invention provides molecular constructs and methods for the temporally specific control of gene expression in plants or in plant pests or pathogens,” the patent application's abstract states. “More specifically, this invention provides plant miRNA genes having novel circadian expression patterns that are useful for designing recombinant DNA constructs for temporally specific expression of at least one gene. Also provided are non-natural transgenic plant cells, plants, and seeds containing in their genome a recombinant DNA construct of this invention.”

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.